{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Li W"],"funding":["NEI NIH HHS","NINDS NIH HHS"],"pagination":["106156"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9958491"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["26(3)"],"pubmed_abstract":["Promoting myelination capacity of endogenous oligodendrocyte precursor cells (OPCs) is a promising therapeutic approach for CNS demyelinating disorders such as Multiple Sclerosis (MS). To aid in the discovery of myelination-promoting compounds, we generated a genome-engineered human pluripotent stem cell (hPSC) line that consists of three reporters: identification-and-purification tag, GFP, and secreted-NanoLuc, driven by the endogenous <i>PDGFRA, PLP1,</i> and <i>MBP</i> genes, respectively. Using this cell line, we established a high-throughput drug screening platform and performed a small-molecule screen, which identified at least two myelination-promoting small-molecule (Ro1138452 and SR2211) that target prostacyclin (IP) receptor and retinoic acid receptor-related orphan receptor γ (R"],"journal":["iScience"],"pubmed_title":["High-throughput screening for myelination promoting compounds using human stem cell-derived oligodendrocyte progenitor cells."],"pmcid":["PMC9958491"],"funding_grant_id":["R00 EY029011","P30 EY001765","R21 NS096668","K99 EY029011"],"pubmed_authors":["Dodge JC","Mao HQ","Ji H","Takaesu F","Berlinicke C","Chen C","Zack DJ","Giera S","Chang X","Li W","Kumar D","Sheng G","McGrath AG","Huang Y","Fang W","Chamling X","Chang C","Madden S","Duan Y"],"additional_accession":[]},"is_claimable":false,"name":"High-throughput screening for myelination promoting compounds using human stem cell-derived oligodendrocyte progenitor cells.","description":"Promoting myelination capacity of endogenous oligodendrocyte precursor cells (OPCs) is a promising therapeutic approach for CNS demyelinating disorders such as Multiple Sclerosis (MS). To aid in the discovery of myelination-promoting compounds, we generated a genome-engineered human pluripotent stem cell (hPSC) line that consists of three reporters: identification-and-purification tag, GFP, and secreted-NanoLuc, driven by the endogenous <i>PDGFRA, PLP1,</i> and <i>MBP</i> genes, respectively. Using this cell line, we established a high-throughput drug screening platform and performed a small-molecule screen, which identified at least two myelination-promoting small-molecule (Ro1138452 and SR2211) that target prostacyclin (IP) receptor and retinoic acid receptor-related orphan receptor γ (R","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Mar","modification":"2026-05-29T05:30:08.18Z","creation":"2025-02-18T23:44:44.386Z"},"accession":"S-EPMC9958491","cross_references":{"pubmed":["36852281"],"doi":["10.1016/j.isci.2023.106156"]}}